- Home
- FGF vs CING Comparison
FGF vs CING Comparison
Compare FGF & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGF
- CING
- Stock Information
- Founded
- FGF 2012
- CING 2012
- Country
- FGF United States
- CING United States
- Employees
- FGF N/A
- CING N/A
- Industry
- FGF Property-Casualty Insurers
- CING Biotechnology: Pharmaceutical Preparations
- Sector
- FGF Finance
- CING Health Care
- Exchange
- FGF Nasdaq
- CING Nasdaq
- Market Cap
- FGF 20.9M
- CING 17.3M
- IPO Year
- FGF N/A
- CING 2021
- Fundamental
- Price
- FGF $20.28
- CING $5.50
- Analyst Decision
- FGF
- CING Strong Buy
- Analyst Count
- FGF 0
- CING 4
- Target Price
- FGF N/A
- CING $30.67
- AVG Volume (30 Days)
- FGF 18.9K
- CING 104.7K
- Earning Date
- FGF 08-13-2025
- CING 08-12-2025
- Dividend Yield
- FGF N/A
- CING N/A
- EPS Growth
- FGF N/A
- CING N/A
- EPS
- FGF N/A
- CING N/A
- Revenue
- FGF $13,260,000.00
- CING N/A
- Revenue This Year
- FGF N/A
- CING N/A
- Revenue Next Year
- FGF N/A
- CING N/A
- P/E Ratio
- FGF N/A
- CING N/A
- Revenue Growth
- FGF N/A
- CING N/A
- 52 Week Low
- FGF $14.21
- CING $1.80
- 52 Week High
- FGF $38.40
- CING $20.83
- Technical
- Relative Strength Index (RSI)
- FGF 54.28
- CING 66.64
- Support Level
- FGF $18.85
- CING $4.25
- Resistance Level
- FGF $27.97
- CING $6.01
- Average True Range (ATR)
- FGF 2.17
- CING 0.34
- MACD
- FGF 0.36
- CING 0.09
- Stochastic Oscillator
- FGF 31.35
- CING 71.02
About FGF FG Financial Group Inc. (NV)
Fundamental Global Inc through its subsidiaries operates as diversified insurance, reinsurance, and investment management holding company. The company's segments includes Insurance and Asset Management. It generates maximum revenue from the Insurance segment.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.